Global Oligonucleotide CDMO Market Research Report 2026(Status and Outlook)
An Oligonucleotide CDMO (Contract Development and Manufacturing Organization) specializes in providing outsourced services related to the development and manufacturing of oligonucleotides. Oligonucleotides are short DNA or RNA molecules used for a variety of applications, including in genetic research, diagnostics, and therapeutics. These organizations are key players in the biopharmaceutical industry, helping companies bring oligonucleotide-based products from the research stage to commercialization.
The global Oligonucleotide CDMO market size was estimated at USD 1250.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 12.50% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Oligonucleotide CDMO market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Oligonucleotide CDMO market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Oligonucleotide CDMO market.
Global Oligonucleotide CDMO Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Agilent
ST Pharm
Bachem
BioSpring
Creative Biogene
Sylentis
Ajinomoto Bio-Pharma
EUROAPI
Veliter
PolyPeptide Group
CordenPharma
Thermofischer
Bio Basic
Genscript
Cytiva
ScinoPharm
CBL
Piramal Pharma
CPC Scientific
Eurogentec
Cambrex
WuXi STA
Market Segmentation (by Type)
APIs and Intermediates
FDF
Market Segmentation (by Application)
Pharmaceutical and Biotechnology Companies
Research Institutes
Others
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Oligonucleotide CDMO Market
Overview of the regional outlook of the Oligonucleotide CDMO Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Oligonucleotide CDMO Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Oligonucleotide CDMO, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Oligonucleotide CDMO market size was estimated at USD 1250.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 12.50% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Oligonucleotide CDMO market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Oligonucleotide CDMO market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Oligonucleotide CDMO market.
Global Oligonucleotide CDMO Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Agilent
ST Pharm
Bachem
BioSpring
Creative Biogene
Sylentis
Ajinomoto Bio-Pharma
EUROAPI
Veliter
PolyPeptide Group
CordenPharma
Thermofischer
Bio Basic
Genscript
Cytiva
ScinoPharm
CBL
Piramal Pharma
CPC Scientific
Eurogentec
Cambrex
WuXi STA
Market Segmentation (by Type)
APIs and Intermediates
FDF
Market Segmentation (by Application)
Pharmaceutical and Biotechnology Companies
Research Institutes
Others
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Oligonucleotide CDMO Market
Overview of the regional outlook of the Oligonucleotide CDMO Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Oligonucleotide CDMO Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Oligonucleotide CDMO, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Oligonucleotide CDMO
1.2 Key Market Segments
1.2.1 Oligonucleotide CDMO Segment by Type
1.2.2 Oligonucleotide CDMO Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 OLIGONUCLEOTIDE CDMO MARKET OVERVIEW
2.1 Global Market Overview
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 OLIGONUCLEOTIDE CDMO MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Oligonucleotide CDMO Product Life Cycle
3.3 Global Oligonucleotide CDMO Revenue Market Share by Company (2020-2025)
3.4 Oligonucleotide CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.5 Headquarters, Areas Served, and Product Types of Major Players
3.6 Oligonucleotide CDMO Market Competitive Situation and Trends
3.6.1 Oligonucleotide CDMO Market Concentration Rate
3.6.2 Global 5 and 10 Largest Oligonucleotide CDMO Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 OLIGONUCLEOTIDE CDMO VALUE CHAIN ANALYSIS
4.1 Oligonucleotide CDMO Value Chain Analysis
4.2 Midstream Market Analysis
4.3 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF OLIGONUCLEOTIDE CDMO MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Oligonucleotide CDMO Market Porter's Five Forces Analysis
6 OLIGONUCLEOTIDE CDMO MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Oligonucleotide CDMO Market by Type (2020-2025)
6.3 Global Oligonucleotide CDMO Market Size Growth Rate by Type (2021-2025)
7 OLIGONUCLEOTIDE CDMO MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Oligonucleotide CDMO Market Size (M USD) by Application (2020-2025)
7.3 Global Oligonucleotide CDMO Market Size Growth Rate by Application (2021-2025)
8 OLIGONUCLEOTIDE CDMO MARKET SEGMENTATION BY REGION
8.1 Global Oligonucleotide CDMO Market Size by Region
8.1.1 Global Oligonucleotide CDMO Market Size by Region
8.1.2 Global Oligonucleotide CDMO Market Size Market Share by Region
8.2 North America
8.2.1 North America Oligonucleotide CDMO Market Size by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Oligonucleotide CDMO Market Size by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Spain
8.4 Asia Pacific
8.4.1 Asia Pacific Oligonucleotide CDMO Market Size by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Oligonucleotide CDMO Market Size by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Oligonucleotide CDMO Market Size by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Agilent
9.1.1 Agilent Basic Information
9.1.2 Agilent Oligonucleotide CDMO Product Overview
9.1.3 Agilent Oligonucleotide CDMO Product Market Performance
9.1.4 Agilent SWOT Analysis
9.1.5 Agilent Business Overview
9.1.6 Agilent Recent Developments
9.2 ST Pharm
9.2.1 ST Pharm Basic Information
9.2.2 ST Pharm Oligonucleotide CDMO Product Overview
9.2.3 ST Pharm Oligonucleotide CDMO Product Market Performance
9.2.4 ST Pharm SWOT Analysis
9.2.5 ST Pharm Business Overview
9.2.6 ST Pharm Recent Developments
9.3 Bachem
9.3.1 Bachem Basic Information
9.3.2 Bachem Oligonucleotide CDMO Product Overview
9.3.3 Bachem Oligonucleotide CDMO Product Market Performance
9.3.4 Bachem SWOT Analysis
9.3.5 Bachem Business Overview
9.3.6 Bachem Recent Developments
9.4 BioSpring
9.4.1 BioSpring Basic Information
9.4.2 BioSpring Oligonucleotide CDMO Product Overview
9.4.3 BioSpring Oligonucleotide CDMO Product Market Performance
9.4.4 BioSpring Business Overview
9.4.5 BioSpring Recent Developments
9.5 Creative Biogene
9.5.1 Creative Biogene Basic Information
9.5.2 Creative Biogene Oligonucleotide CDMO Product Overview
9.5.3 Creative Biogene Oligonucleotide CDMO Product Market Performance
9.5.4 Creative Biogene Business Overview
9.5.5 Creative Biogene Recent Developments
9.6 Sylentis
9.6.1 Sylentis Basic Information
9.6.2 Sylentis Oligonucleotide CDMO Product Overview
9.6.3 Sylentis Oligonucleotide CDMO Product Market Performance
9.6.4 Sylentis Business Overview
9.6.5 Sylentis Recent Developments
9.7 Ajinomoto Bio-Pharma
9.7.1 Ajinomoto Bio-Pharma Basic Information
9.7.2 Ajinomoto Bio-Pharma Oligonucleotide CDMO Product Overview
9.7.3 Ajinomoto Bio-Pharma Oligonucleotide CDMO Product Market Performance
9.7.4 Ajinomoto Bio-Pharma Business Overview
9.7.5 Ajinomoto Bio-Pharma Recent Developments
9.8 EUROAPI
9.8.1 EUROAPI Basic Information
9.8.2 EUROAPI Oligonucleotide CDMO Product Overview
9.8.3 EUROAPI Oligonucleotide CDMO Product Market Performance
9.8.4 EUROAPI Business Overview
9.8.5 EUROAPI Recent Developments
9.9 Veliter
9.9.1 Veliter Basic Information
9.9.2 Veliter Oligonucleotide CDMO Product Overview
9.9.3 Veliter Oligonucleotide CDMO Product Market Performance
9.9.4 Veliter Business Overview
9.9.5 Veliter Recent Developments
9.10 PolyPeptide Group
9.10.1 PolyPeptide Group Basic Information
9.10.2 PolyPeptide Group Oligonucleotide CDMO Product Overview
9.10.3 PolyPeptide Group Oligonucleotide CDMO Product Market Performance
9.10.4 PolyPeptide Group Business Overview
9.10.5 PolyPeptide Group Recent Developments
9.11 CordenPharma
9.11.1 CordenPharma Basic Information
9.11.2 CordenPharma Oligonucleotide CDMO Product Overview
9.11.3 CordenPharma Oligonucleotide CDMO Product Market Performance
9.11.4 CordenPharma Business Overview
9.11.5 CordenPharma Recent Developments
9.12 Thermofischer
9.12.1 Thermofischer Basic Information
9.12.2 Thermofischer Oligonucleotide CDMO Product Overview
9.12.3 Thermofischer Oligonucleotide CDMO Product Market Performance
9.12.4 Thermofischer Business Overview
9.12.5 Thermofischer Recent Developments
9.13 Bio Basic
9.13.1 Bio Basic Basic Information
9.13.2 Bio Basic Oligonucleotide CDMO Product Overview
9.13.3 Bio Basic Oligonucleotide CDMO Product Market Performance
9.13.4 Bio Basic Business Overview
9.13.5 Bio Basic Recent Developments
9.14 Genscript
9.14.1 Genscript Basic Information
9.14.2 Genscript Oligonucleotide CDMO Product Overview
9.14.3 Genscript Oligonucleotide CDMO Product Market Performance
9.14.4 Genscript Business Overview
9.14.5 Genscript Recent Developments
9.15 Cytiva
9.15.1 Cytiva Basic Information
9.15.2 Cytiva Oligonucleotide CDMO Product Overview
9.15.3 Cytiva Oligonucleotide CDMO Product Market Performance
9.15.4 Cytiva Business Overview
9.15.5 Cytiva Recent Developments
9.16 ScinoPharm
9.16.1 ScinoPharm Basic Information
9.16.2 ScinoPharm Oligonucleotide CDMO Product Overview
9.16.3 ScinoPharm Oligonucleotide CDMO Product Market Performance
9.16.4 ScinoPharm Business Overview
9.16.5 ScinoPharm Recent Developments
9.17 CBL
9.17.1 CBL Basic Information
9.17.2 CBL Oligonucleotide CDMO Product Overview
9.17.3 CBL Oligonucleotide CDMO Product Market Performance
9.17.4 CBL Business Overview
9.17.5 CBL Recent Developments
9.18 Piramal Pharma
9.18.1 Piramal Pharma Basic Information
9.18.2 Piramal Pharma Oligonucleotide CDMO Product Overview
9.18.3 Piramal Pharma Oligonucleotide CDMO Product Market Performance
9.18.4 Piramal Pharma Business Overview
9.18.5 Piramal Pharma Recent Developments
9.19 CPC Scientific
9.19.1 CPC Scientific Basic Information
9.19.2 CPC Scientific Oligonucleotide CDMO Product Overview
9.19.3 CPC Scientific Oligonucleotide CDMO Product Market Performance
9.19.4 CPC Scientific Business Overview
9.19.5 CPC Scientific Recent Developments
9.20 Eurogentec
9.20.1 Eurogentec Basic Information
9.20.2 Eurogentec Oligonucleotide CDMO Product Overview
9.20.3 Eurogentec Oligonucleotide CDMO Product Market Performance
9.20.4 Eurogentec Business Overview
9.20.5 Eurogentec Recent Developments
9.21 Cambrex
9.21.1 Cambrex Basic Information
9.21.2 Cambrex Oligonucleotide CDMO Product Overview
9.21.3 Cambrex Oligonucleotide CDMO Product Market Performance
9.21.4 Cambrex Business Overview
9.21.5 Cambrex Recent Developments
9.22 WuXi STA
9.22.1 WuXi STA Basic Information
9.22.2 WuXi STA Oligonucleotide CDMO Product Overview
9.22.3 WuXi STA Oligonucleotide CDMO Product Market Performance
9.22.4 WuXi STA Business Overview
9.22.5 WuXi STA Recent Developments
10 OLIGONUCLEOTIDE CDMO MARKET FORECAST BY REGION
10.1 Global Oligonucleotide CDMO Market Size Forecast
10.2 Global Oligonucleotide CDMO Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Oligonucleotide CDMO Market Size Forecast by Country
10.2.3 Asia Pacific Oligonucleotide CDMO Market Size Forecast by Region
10.2.4 South America Oligonucleotide CDMO Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Sales of Oligonucleotide CDMO by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
11.1 Global Oligonucleotide CDMO Market Forecast by Type (2026-2035)
11.1.1 Global Oligonucleotide CDMO Market Size Forecast by Type (2026-2035)
11.2 Global Oligonucleotide CDMO Market Forecast by Application (2026-2035)
11.2.1 Global Oligonucleotide CDMO Market Size (M USD) Forecast by Application (2026-2035)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Oligonucleotide CDMO
1.2 Key Market Segments
1.2.1 Oligonucleotide CDMO Segment by Type
1.2.2 Oligonucleotide CDMO Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 OLIGONUCLEOTIDE CDMO MARKET OVERVIEW
2.1 Global Market Overview
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 OLIGONUCLEOTIDE CDMO MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Oligonucleotide CDMO Product Life Cycle
3.3 Global Oligonucleotide CDMO Revenue Market Share by Company (2020-2025)
3.4 Oligonucleotide CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.5 Headquarters, Areas Served, and Product Types of Major Players
3.6 Oligonucleotide CDMO Market Competitive Situation and Trends
3.6.1 Oligonucleotide CDMO Market Concentration Rate
3.6.2 Global 5 and 10 Largest Oligonucleotide CDMO Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 OLIGONUCLEOTIDE CDMO VALUE CHAIN ANALYSIS
4.1 Oligonucleotide CDMO Value Chain Analysis
4.2 Midstream Market Analysis
4.3 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF OLIGONUCLEOTIDE CDMO MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Oligonucleotide CDMO Market Porter's Five Forces Analysis
6 OLIGONUCLEOTIDE CDMO MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Oligonucleotide CDMO Market by Type (2020-2025)
6.3 Global Oligonucleotide CDMO Market Size Growth Rate by Type (2021-2025)
7 OLIGONUCLEOTIDE CDMO MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Oligonucleotide CDMO Market Size (M USD) by Application (2020-2025)
7.3 Global Oligonucleotide CDMO Market Size Growth Rate by Application (2021-2025)
8 OLIGONUCLEOTIDE CDMO MARKET SEGMENTATION BY REGION
8.1 Global Oligonucleotide CDMO Market Size by Region
8.1.1 Global Oligonucleotide CDMO Market Size by Region
8.1.2 Global Oligonucleotide CDMO Market Size Market Share by Region
8.2 North America
8.2.1 North America Oligonucleotide CDMO Market Size by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Oligonucleotide CDMO Market Size by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Spain
8.4 Asia Pacific
8.4.1 Asia Pacific Oligonucleotide CDMO Market Size by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Oligonucleotide CDMO Market Size by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Oligonucleotide CDMO Market Size by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Agilent
9.1.1 Agilent Basic Information
9.1.2 Agilent Oligonucleotide CDMO Product Overview
9.1.3 Agilent Oligonucleotide CDMO Product Market Performance
9.1.4 Agilent SWOT Analysis
9.1.5 Agilent Business Overview
9.1.6 Agilent Recent Developments
9.2 ST Pharm
9.2.1 ST Pharm Basic Information
9.2.2 ST Pharm Oligonucleotide CDMO Product Overview
9.2.3 ST Pharm Oligonucleotide CDMO Product Market Performance
9.2.4 ST Pharm SWOT Analysis
9.2.5 ST Pharm Business Overview
9.2.6 ST Pharm Recent Developments
9.3 Bachem
9.3.1 Bachem Basic Information
9.3.2 Bachem Oligonucleotide CDMO Product Overview
9.3.3 Bachem Oligonucleotide CDMO Product Market Performance
9.3.4 Bachem SWOT Analysis
9.3.5 Bachem Business Overview
9.3.6 Bachem Recent Developments
9.4 BioSpring
9.4.1 BioSpring Basic Information
9.4.2 BioSpring Oligonucleotide CDMO Product Overview
9.4.3 BioSpring Oligonucleotide CDMO Product Market Performance
9.4.4 BioSpring Business Overview
9.4.5 BioSpring Recent Developments
9.5 Creative Biogene
9.5.1 Creative Biogene Basic Information
9.5.2 Creative Biogene Oligonucleotide CDMO Product Overview
9.5.3 Creative Biogene Oligonucleotide CDMO Product Market Performance
9.5.4 Creative Biogene Business Overview
9.5.5 Creative Biogene Recent Developments
9.6 Sylentis
9.6.1 Sylentis Basic Information
9.6.2 Sylentis Oligonucleotide CDMO Product Overview
9.6.3 Sylentis Oligonucleotide CDMO Product Market Performance
9.6.4 Sylentis Business Overview
9.6.5 Sylentis Recent Developments
9.7 Ajinomoto Bio-Pharma
9.7.1 Ajinomoto Bio-Pharma Basic Information
9.7.2 Ajinomoto Bio-Pharma Oligonucleotide CDMO Product Overview
9.7.3 Ajinomoto Bio-Pharma Oligonucleotide CDMO Product Market Performance
9.7.4 Ajinomoto Bio-Pharma Business Overview
9.7.5 Ajinomoto Bio-Pharma Recent Developments
9.8 EUROAPI
9.8.1 EUROAPI Basic Information
9.8.2 EUROAPI Oligonucleotide CDMO Product Overview
9.8.3 EUROAPI Oligonucleotide CDMO Product Market Performance
9.8.4 EUROAPI Business Overview
9.8.5 EUROAPI Recent Developments
9.9 Veliter
9.9.1 Veliter Basic Information
9.9.2 Veliter Oligonucleotide CDMO Product Overview
9.9.3 Veliter Oligonucleotide CDMO Product Market Performance
9.9.4 Veliter Business Overview
9.9.5 Veliter Recent Developments
9.10 PolyPeptide Group
9.10.1 PolyPeptide Group Basic Information
9.10.2 PolyPeptide Group Oligonucleotide CDMO Product Overview
9.10.3 PolyPeptide Group Oligonucleotide CDMO Product Market Performance
9.10.4 PolyPeptide Group Business Overview
9.10.5 PolyPeptide Group Recent Developments
9.11 CordenPharma
9.11.1 CordenPharma Basic Information
9.11.2 CordenPharma Oligonucleotide CDMO Product Overview
9.11.3 CordenPharma Oligonucleotide CDMO Product Market Performance
9.11.4 CordenPharma Business Overview
9.11.5 CordenPharma Recent Developments
9.12 Thermofischer
9.12.1 Thermofischer Basic Information
9.12.2 Thermofischer Oligonucleotide CDMO Product Overview
9.12.3 Thermofischer Oligonucleotide CDMO Product Market Performance
9.12.4 Thermofischer Business Overview
9.12.5 Thermofischer Recent Developments
9.13 Bio Basic
9.13.1 Bio Basic Basic Information
9.13.2 Bio Basic Oligonucleotide CDMO Product Overview
9.13.3 Bio Basic Oligonucleotide CDMO Product Market Performance
9.13.4 Bio Basic Business Overview
9.13.5 Bio Basic Recent Developments
9.14 Genscript
9.14.1 Genscript Basic Information
9.14.2 Genscript Oligonucleotide CDMO Product Overview
9.14.3 Genscript Oligonucleotide CDMO Product Market Performance
9.14.4 Genscript Business Overview
9.14.5 Genscript Recent Developments
9.15 Cytiva
9.15.1 Cytiva Basic Information
9.15.2 Cytiva Oligonucleotide CDMO Product Overview
9.15.3 Cytiva Oligonucleotide CDMO Product Market Performance
9.15.4 Cytiva Business Overview
9.15.5 Cytiva Recent Developments
9.16 ScinoPharm
9.16.1 ScinoPharm Basic Information
9.16.2 ScinoPharm Oligonucleotide CDMO Product Overview
9.16.3 ScinoPharm Oligonucleotide CDMO Product Market Performance
9.16.4 ScinoPharm Business Overview
9.16.5 ScinoPharm Recent Developments
9.17 CBL
9.17.1 CBL Basic Information
9.17.2 CBL Oligonucleotide CDMO Product Overview
9.17.3 CBL Oligonucleotide CDMO Product Market Performance
9.17.4 CBL Business Overview
9.17.5 CBL Recent Developments
9.18 Piramal Pharma
9.18.1 Piramal Pharma Basic Information
9.18.2 Piramal Pharma Oligonucleotide CDMO Product Overview
9.18.3 Piramal Pharma Oligonucleotide CDMO Product Market Performance
9.18.4 Piramal Pharma Business Overview
9.18.5 Piramal Pharma Recent Developments
9.19 CPC Scientific
9.19.1 CPC Scientific Basic Information
9.19.2 CPC Scientific Oligonucleotide CDMO Product Overview
9.19.3 CPC Scientific Oligonucleotide CDMO Product Market Performance
9.19.4 CPC Scientific Business Overview
9.19.5 CPC Scientific Recent Developments
9.20 Eurogentec
9.20.1 Eurogentec Basic Information
9.20.2 Eurogentec Oligonucleotide CDMO Product Overview
9.20.3 Eurogentec Oligonucleotide CDMO Product Market Performance
9.20.4 Eurogentec Business Overview
9.20.5 Eurogentec Recent Developments
9.21 Cambrex
9.21.1 Cambrex Basic Information
9.21.2 Cambrex Oligonucleotide CDMO Product Overview
9.21.3 Cambrex Oligonucleotide CDMO Product Market Performance
9.21.4 Cambrex Business Overview
9.21.5 Cambrex Recent Developments
9.22 WuXi STA
9.22.1 WuXi STA Basic Information
9.22.2 WuXi STA Oligonucleotide CDMO Product Overview
9.22.3 WuXi STA Oligonucleotide CDMO Product Market Performance
9.22.4 WuXi STA Business Overview
9.22.5 WuXi STA Recent Developments
10 OLIGONUCLEOTIDE CDMO MARKET FORECAST BY REGION
10.1 Global Oligonucleotide CDMO Market Size Forecast
10.2 Global Oligonucleotide CDMO Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Oligonucleotide CDMO Market Size Forecast by Country
10.2.3 Asia Pacific Oligonucleotide CDMO Market Size Forecast by Region
10.2.4 South America Oligonucleotide CDMO Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Sales of Oligonucleotide CDMO by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
11.1 Global Oligonucleotide CDMO Market Forecast by Type (2026-2035)
11.1.1 Global Oligonucleotide CDMO Market Size Forecast by Type (2026-2035)
11.2 Global Oligonucleotide CDMO Market Forecast by Application (2026-2035)
11.2.1 Global Oligonucleotide CDMO Market Size (M USD) Forecast by Application (2026-2035)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Oligonucleotide CDMO Market Size by Type (M USD)
Table 4. Global Oligonucleotide CDMO Market Size by Application
Table 5. Oligonucleotide CDMO Market Size Comparison by Region (M USD)
Table 6. Global Oligonucleotide CDMO Revenue (M USD) by Company (2020-2025)
Table 7. Global Oligonucleotide CDMO Revenue Share by Company (2020-2025)
Table 8. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide CDMO as of 2025)
Table 9. Headquarters, Areas Served, and Product Types of Major Players
Table 10. Product Type of Major Players
Table 11. Global Oligonucleotide CDMO Company Market Concentration Ratio (CR5 and HHI)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Midstream Market Analysis
Table 14. Downstream Customer Analysis
Table 15. Key Development Trends
Table 16. Driving Factors
Table 17. Oligonucleotide CDMO Market Challenges
Table 18. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 19. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 20. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 21. Global Oligonucleotide CDMO Market Size by Type (M USD)
Table 22. Global Oligonucleotide CDMO Market Size (M USD) by Type (2020-2025)
Table 23. Global Oligonucleotide CDMO Market Share by Type (2020-2025)
Table 24. Global Oligonucleotide CDMO Market Size Growth Rate by Type (2021-2025)
Table 25. Global Oligonucleotide CDMO Market Size by Application
Table 26. Global Oligonucleotide CDMO Market Size by Application (2020-2025) & (M USD)
Table 27. Global Oligonucleotide CDMO Market Share by Application (2020-2025)
Table 28. Global Oligonucleotide CDMO Market Size Growth Rate by Application (2021-2025)
Table 29. Global Oligonucleotide CDMO Market Size by Region (2020-2025) & (M USD)
Table 30. Global Oligonucleotide CDMO Market Size Market Share by Region (2020-2025)
Table 31. North America Oligonucleotide CDMO Market Size by Country (2020-2025) & (M USD)
Table 32. Europe Oligonucleotide CDMO Market Size by Country (2020-2025) & (M USD)
Table 33. Asia Pacific Oligonucleotide CDMO Market Size by Region (2020-2025) & (M USD)
Table 34. South America Oligonucleotide CDMO Market Size by Country (2020-2025) & (M USD)
Table 35. Middle East and Africa Oligonucleotide CDMO Market Size by Region (2020-2025) & (M USD)
Table 36. Agilent Basic Information
Table 37. Agilent Oligonucleotide CDMO Product Overview
Table 38. Agilent Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 39. Agilent SWOT Analysis
Table 40. Agilent Business Overview
Table 41. Agilent Recent Developments
Table 42. ST Pharm Basic Information
Table 43. ST Pharm Oligonucleotide CDMO Product Overview
Table 44. ST Pharm Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 45. ST Pharm SWOT Analysis
Table 46. ST Pharm Business Overview
Table 47. ST Pharm Recent Developments
Table 48. Bachem Basic Information
Table 49. Bachem Oligonucleotide CDMO Product Overview
Table 50. Bachem Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 51. Bachem SWOT Analysis
Table 52. Bachem Business Overview
Table 53. Bachem Recent Developments
Table 54. BioSpring Basic Information
Table 55. BioSpring Oligonucleotide CDMO Product Overview
Table 56. BioSpring Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 57. BioSpring Business Overview
Table 58. BioSpring Recent Developments
Table 59. Creative Biogene Basic Information
Table 60. Creative Biogene Oligonucleotide CDMO Product Overview
Table 61. Creative Biogene Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 62. Creative Biogene Business Overview
Table 63. Creative Biogene Recent Developments
Table 64. Sylentis Basic Information
Table 65. Sylentis Oligonucleotide CDMO Product Overview
Table 66. Sylentis Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 67. Sylentis Business Overview
Table 68. Sylentis Recent Developments
Table 69. Ajinomoto Bio-Pharma Basic Information
Table 70. Ajinomoto Bio-Pharma Oligonucleotide CDMO Product Overview
Table 71. Ajinomoto Bio-Pharma Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 72. Ajinomoto Bio-Pharma Business Overview
Table 73. Ajinomoto Bio-Pharma Recent Developments
Table 74. EUROAPI Basic Information
Table 75. EUROAPI Oligonucleotide CDMO Product Overview
Table 76. EUROAPI Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 77. EUROAPI Business Overview
Table 78. EUROAPI Recent Developments
Table 79. Veliter Basic Information
Table 80. Veliter Oligonucleotide CDMO Product Overview
Table 81. Veliter Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 82. Veliter Business Overview
Table 83. Veliter Recent Developments
Table 84. PolyPeptide Group Basic Information
Table 85. PolyPeptide Group Oligonucleotide CDMO Product Overview
Table 86. PolyPeptide Group Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 87. PolyPeptide Group Business Overview
Table 88. PolyPeptide Group Recent Developments
Table 89. CordenPharma Basic Information
Table 90. CordenPharma Oligonucleotide CDMO Product Overview
Table 91. CordenPharma Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 92. CordenPharma Business Overview
Table 93. CordenPharma Recent Developments
Table 94. Thermofischer Basic Information
Table 95. Thermofischer Oligonucleotide CDMO Product Overview
Table 96. Thermofischer Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 97. Thermofischer Business Overview
Table 98. Thermofischer Recent Developments
Table 99. Bio Basic Basic Information
Table 100. Bio Basic Oligonucleotide CDMO Product Overview
Table 101. Bio Basic Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 102. Bio Basic Business Overview
Table 103. Bio Basic Recent Developments
Table 104. Genscript Basic Information
Table 105. Genscript Oligonucleotide CDMO Product Overview
Table 106. Genscript Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 107. Genscript Business Overview
Table 108. Genscript Recent Developments
Table 109. Cytiva Basic Information
Table 110. Cytiva Oligonucleotide CDMO Product Overview
Table 111. Cytiva Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 112. Cytiva Business Overview
Table 113. Cytiva Recent Developments
Table 114. ScinoPharm Basic Information
Table 115. ScinoPharm Oligonucleotide CDMO Product Overview
Table 116. ScinoPharm Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 117. ScinoPharm Business Overview
Table 118. ScinoPharm Recent Developments
Table 119. CBL Basic Information
Table 120. CBL Oligonucleotide CDMO Product Overview
Table 121. CBL Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 122. CBL Business Overview
Table 123. CBL Recent Developments
Table 124. Piramal Pharma Basic Information
Table 125. Piramal Pharma Oligonucleotide CDMO Product Overview
Table 126. Piramal Pharma Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 127. Piramal Pharma Business Overview
Table 128. Piramal Pharma Recent Developments
Table 129. CPC Scientific Basic Information
Table 130. CPC Scientific Oligonucleotide CDMO Product Overview
Table 131. CPC Scientific Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 132. CPC Scientific Business Overview
Table 133. CPC Scientific Recent Developments
Table 134. Eurogentec Basic Information
Table 135. Eurogentec Oligonucleotide CDMO Product Overview
Table 136. Eurogentec Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 137. Eurogentec Business Overview
Table 138. Eurogentec Recent Developments
Table 139. Cambrex Basic Information
Table 140. Cambrex Oligonucleotide CDMO Product Overview
Table 141. Cambrex Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 142. Cambrex Business Overview
Table 143. Cambrex Recent Developments
Table 144. WuXi STA Basic Information
Table 145. WuXi STA Oligonucleotide CDMO Product Overview
Table 146. WuXi STA Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 147. WuXi STA Business Overview
Table 148. WuXi STA Recent Developments
Table 149. Global Oligonucleotide CDMO Market Size Forecast by Region (2026-2035) & (M USD)
Table 150. North America Oligonucleotide CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 151. Europe Oligonucleotide CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 152. Asia Pacific Oligonucleotide CDMO Market Size Forecast by Region (2026-2035) & (M USD)
Table 153. South America Oligonucleotide CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 154. Middle East and Africa Oligonucleotide CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 155. Global Oligonucleotide CDMO Market Size Forecast by Type (2026-2035) & (M USD)
Table 156. Global Oligonucleotide CDMO Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Oligonucleotide CDMO Market Size by Type (M USD)
Table 4. Global Oligonucleotide CDMO Market Size by Application
Table 5. Oligonucleotide CDMO Market Size Comparison by Region (M USD)
Table 6. Global Oligonucleotide CDMO Revenue (M USD) by Company (2020-2025)
Table 7. Global Oligonucleotide CDMO Revenue Share by Company (2020-2025)
Table 8. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide CDMO as of 2025)
Table 9. Headquarters, Areas Served, and Product Types of Major Players
Table 10. Product Type of Major Players
Table 11. Global Oligonucleotide CDMO Company Market Concentration Ratio (CR5 and HHI)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Midstream Market Analysis
Table 14. Downstream Customer Analysis
Table 15. Key Development Trends
Table 16. Driving Factors
Table 17. Oligonucleotide CDMO Market Challenges
Table 18. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 19. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 20. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 21. Global Oligonucleotide CDMO Market Size by Type (M USD)
Table 22. Global Oligonucleotide CDMO Market Size (M USD) by Type (2020-2025)
Table 23. Global Oligonucleotide CDMO Market Share by Type (2020-2025)
Table 24. Global Oligonucleotide CDMO Market Size Growth Rate by Type (2021-2025)
Table 25. Global Oligonucleotide CDMO Market Size by Application
Table 26. Global Oligonucleotide CDMO Market Size by Application (2020-2025) & (M USD)
Table 27. Global Oligonucleotide CDMO Market Share by Application (2020-2025)
Table 28. Global Oligonucleotide CDMO Market Size Growth Rate by Application (2021-2025)
Table 29. Global Oligonucleotide CDMO Market Size by Region (2020-2025) & (M USD)
Table 30. Global Oligonucleotide CDMO Market Size Market Share by Region (2020-2025)
Table 31. North America Oligonucleotide CDMO Market Size by Country (2020-2025) & (M USD)
Table 32. Europe Oligonucleotide CDMO Market Size by Country (2020-2025) & (M USD)
Table 33. Asia Pacific Oligonucleotide CDMO Market Size by Region (2020-2025) & (M USD)
Table 34. South America Oligonucleotide CDMO Market Size by Country (2020-2025) & (M USD)
Table 35. Middle East and Africa Oligonucleotide CDMO Market Size by Region (2020-2025) & (M USD)
Table 36. Agilent Basic Information
Table 37. Agilent Oligonucleotide CDMO Product Overview
Table 38. Agilent Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 39. Agilent SWOT Analysis
Table 40. Agilent Business Overview
Table 41. Agilent Recent Developments
Table 42. ST Pharm Basic Information
Table 43. ST Pharm Oligonucleotide CDMO Product Overview
Table 44. ST Pharm Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 45. ST Pharm SWOT Analysis
Table 46. ST Pharm Business Overview
Table 47. ST Pharm Recent Developments
Table 48. Bachem Basic Information
Table 49. Bachem Oligonucleotide CDMO Product Overview
Table 50. Bachem Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 51. Bachem SWOT Analysis
Table 52. Bachem Business Overview
Table 53. Bachem Recent Developments
Table 54. BioSpring Basic Information
Table 55. BioSpring Oligonucleotide CDMO Product Overview
Table 56. BioSpring Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 57. BioSpring Business Overview
Table 58. BioSpring Recent Developments
Table 59. Creative Biogene Basic Information
Table 60. Creative Biogene Oligonucleotide CDMO Product Overview
Table 61. Creative Biogene Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 62. Creative Biogene Business Overview
Table 63. Creative Biogene Recent Developments
Table 64. Sylentis Basic Information
Table 65. Sylentis Oligonucleotide CDMO Product Overview
Table 66. Sylentis Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 67. Sylentis Business Overview
Table 68. Sylentis Recent Developments
Table 69. Ajinomoto Bio-Pharma Basic Information
Table 70. Ajinomoto Bio-Pharma Oligonucleotide CDMO Product Overview
Table 71. Ajinomoto Bio-Pharma Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 72. Ajinomoto Bio-Pharma Business Overview
Table 73. Ajinomoto Bio-Pharma Recent Developments
Table 74. EUROAPI Basic Information
Table 75. EUROAPI Oligonucleotide CDMO Product Overview
Table 76. EUROAPI Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 77. EUROAPI Business Overview
Table 78. EUROAPI Recent Developments
Table 79. Veliter Basic Information
Table 80. Veliter Oligonucleotide CDMO Product Overview
Table 81. Veliter Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 82. Veliter Business Overview
Table 83. Veliter Recent Developments
Table 84. PolyPeptide Group Basic Information
Table 85. PolyPeptide Group Oligonucleotide CDMO Product Overview
Table 86. PolyPeptide Group Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 87. PolyPeptide Group Business Overview
Table 88. PolyPeptide Group Recent Developments
Table 89. CordenPharma Basic Information
Table 90. CordenPharma Oligonucleotide CDMO Product Overview
Table 91. CordenPharma Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 92. CordenPharma Business Overview
Table 93. CordenPharma Recent Developments
Table 94. Thermofischer Basic Information
Table 95. Thermofischer Oligonucleotide CDMO Product Overview
Table 96. Thermofischer Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 97. Thermofischer Business Overview
Table 98. Thermofischer Recent Developments
Table 99. Bio Basic Basic Information
Table 100. Bio Basic Oligonucleotide CDMO Product Overview
Table 101. Bio Basic Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 102. Bio Basic Business Overview
Table 103. Bio Basic Recent Developments
Table 104. Genscript Basic Information
Table 105. Genscript Oligonucleotide CDMO Product Overview
Table 106. Genscript Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 107. Genscript Business Overview
Table 108. Genscript Recent Developments
Table 109. Cytiva Basic Information
Table 110. Cytiva Oligonucleotide CDMO Product Overview
Table 111. Cytiva Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 112. Cytiva Business Overview
Table 113. Cytiva Recent Developments
Table 114. ScinoPharm Basic Information
Table 115. ScinoPharm Oligonucleotide CDMO Product Overview
Table 116. ScinoPharm Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 117. ScinoPharm Business Overview
Table 118. ScinoPharm Recent Developments
Table 119. CBL Basic Information
Table 120. CBL Oligonucleotide CDMO Product Overview
Table 121. CBL Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 122. CBL Business Overview
Table 123. CBL Recent Developments
Table 124. Piramal Pharma Basic Information
Table 125. Piramal Pharma Oligonucleotide CDMO Product Overview
Table 126. Piramal Pharma Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 127. Piramal Pharma Business Overview
Table 128. Piramal Pharma Recent Developments
Table 129. CPC Scientific Basic Information
Table 130. CPC Scientific Oligonucleotide CDMO Product Overview
Table 131. CPC Scientific Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 132. CPC Scientific Business Overview
Table 133. CPC Scientific Recent Developments
Table 134. Eurogentec Basic Information
Table 135. Eurogentec Oligonucleotide CDMO Product Overview
Table 136. Eurogentec Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 137. Eurogentec Business Overview
Table 138. Eurogentec Recent Developments
Table 139. Cambrex Basic Information
Table 140. Cambrex Oligonucleotide CDMO Product Overview
Table 141. Cambrex Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 142. Cambrex Business Overview
Table 143. Cambrex Recent Developments
Table 144. WuXi STA Basic Information
Table 145. WuXi STA Oligonucleotide CDMO Product Overview
Table 146. WuXi STA Oligonucleotide CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 147. WuXi STA Business Overview
Table 148. WuXi STA Recent Developments
Table 149. Global Oligonucleotide CDMO Market Size Forecast by Region (2026-2035) & (M USD)
Table 150. North America Oligonucleotide CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 151. Europe Oligonucleotide CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 152. Asia Pacific Oligonucleotide CDMO Market Size Forecast by Region (2026-2035) & (M USD)
Table 153. South America Oligonucleotide CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 154. Middle East and Africa Oligonucleotide CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 155. Global Oligonucleotide CDMO Market Size Forecast by Type (2026-2035) & (M USD)
Table 156. Global Oligonucleotide CDMO Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Industry Chain of Oligonucleotide CDMO
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Oligonucleotide CDMO Market Size (M USD), 2025-2035
Figure 5. Global Oligonucleotide CDMO Market Size (M USD) (2020-2035)
Figure 6. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 8. Evaluation Matrix of Regional Market Development Potential
Figure 9. Oligonucleotide CDMO Market Size by Country (M USD)
Figure 10. Company Assessment Quadrant
Figure 11. Global Oligonucleotide CDMO Product Life Cycle
Figure 12. Global Oligonucleotide CDMO Revenue Share by Company in 2025
Figure 13. Oligonucleotide CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 14. The Global 5 and 10 Largest Players: Market Share by Oligonucleotide CDMO Revenue in 2025
Figure 15. Value Chain Map of Oligonucleotide CDMO
Figure 16. Global Oligonucleotide CDMO Market PEST Analysis
Figure 17. Global Oligonucleotide CDMO Market Porter's Five Forces Analysis
Figure 18. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 19. Global Oligonucleotide CDMO Market Share by Type
Figure 20. Market Share of Oligonucleotide CDMO by Type (2020-2025)
Figure 21. Global Oligonucleotide CDMO Market Size Growth Rate by Type (2021-2025)
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Oligonucleotide CDMO Market Share by Application
Figure 24. Global Oligonucleotide CDMO Market Share by Application (2020-2025)
Figure 25. Global Oligonucleotide CDMO Market Share by Application in 2024
Figure 26. Global Oligonucleotide CDMO Market Size Growth Rate by Application (2021-2025)
Figure 27. Global Oligonucleotide CDMO Market Size Market Share by Region (2020-2025)
Figure 28. North America Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 29. North America Oligonucleotide CDMO Market Size Market Share by Country in 2024
Figure 30. U.S. Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 31. Canada Oligonucleotide CDMO Market Size (M USD) and Growth Rate (2020-2025)
Figure 32. Mexico Oligonucleotide CDMO Market Size (M USD) and Growth Rate (2020-2025)
Figure 33. Europe Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 34. Europe Oligonucleotide CDMO Market Share by Country in 2024
Figure 35. Germany Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 36. France Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 37. U.K. Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 38. Italy Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 39. Spain Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 40. Asia Pacific Oligonucleotide CDMO Market Size and Growth Rate (M USD)
Figure 41. Asia Pacific Oligonucleotide CDMO Market Size Market Share by Region in 2024
Figure 42. China Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 43. Japan Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. South Korea Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 45. India Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 46. Southeast Asia Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. South America Oligonucleotide CDMO Market Size and Growth Rate (M USD)
Figure 48. South America Oligonucleotide CDMO Market Size Market Share by Country in 2024
Figure 49. Brazil Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 50. Argentina Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 51. Columbia Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 52. Middle East and Africa Oligonucleotide CDMO Market Size and Growth Rate (M USD)
Figure 53. Middle East and Africa Oligonucleotide CDMO Market Size Market Share by Region in 2024
Figure 54. Saudi Arabia Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 55. UAE Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 56. Egypt Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. Nigeria Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 58. South Africa Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. Global Oligonucleotide CDMO Market Size Forecast by Value (2020-2035) & (M USD)
Figure 60. Global Oligonucleotide CDMO Market Share Forecast by Type (2026-2035)
Figure 61. Global Oligonucleotide CDMO Market Share Forecast by Application (2026-2035)
Figure 1. Industry Chain of Oligonucleotide CDMO
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Oligonucleotide CDMO Market Size (M USD), 2025-2035
Figure 5. Global Oligonucleotide CDMO Market Size (M USD) (2020-2035)
Figure 6. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 8. Evaluation Matrix of Regional Market Development Potential
Figure 9. Oligonucleotide CDMO Market Size by Country (M USD)
Figure 10. Company Assessment Quadrant
Figure 11. Global Oligonucleotide CDMO Product Life Cycle
Figure 12. Global Oligonucleotide CDMO Revenue Share by Company in 2025
Figure 13. Oligonucleotide CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 14. The Global 5 and 10 Largest Players: Market Share by Oligonucleotide CDMO Revenue in 2025
Figure 15. Value Chain Map of Oligonucleotide CDMO
Figure 16. Global Oligonucleotide CDMO Market PEST Analysis
Figure 17. Global Oligonucleotide CDMO Market Porter's Five Forces Analysis
Figure 18. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 19. Global Oligonucleotide CDMO Market Share by Type
Figure 20. Market Share of Oligonucleotide CDMO by Type (2020-2025)
Figure 21. Global Oligonucleotide CDMO Market Size Growth Rate by Type (2021-2025)
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Oligonucleotide CDMO Market Share by Application
Figure 24. Global Oligonucleotide CDMO Market Share by Application (2020-2025)
Figure 25. Global Oligonucleotide CDMO Market Share by Application in 2024
Figure 26. Global Oligonucleotide CDMO Market Size Growth Rate by Application (2021-2025)
Figure 27. Global Oligonucleotide CDMO Market Size Market Share by Region (2020-2025)
Figure 28. North America Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 29. North America Oligonucleotide CDMO Market Size Market Share by Country in 2024
Figure 30. U.S. Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 31. Canada Oligonucleotide CDMO Market Size (M USD) and Growth Rate (2020-2025)
Figure 32. Mexico Oligonucleotide CDMO Market Size (M USD) and Growth Rate (2020-2025)
Figure 33. Europe Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 34. Europe Oligonucleotide CDMO Market Share by Country in 2024
Figure 35. Germany Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 36. France Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 37. U.K. Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 38. Italy Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 39. Spain Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 40. Asia Pacific Oligonucleotide CDMO Market Size and Growth Rate (M USD)
Figure 41. Asia Pacific Oligonucleotide CDMO Market Size Market Share by Region in 2024
Figure 42. China Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 43. Japan Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. South Korea Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 45. India Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 46. Southeast Asia Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. South America Oligonucleotide CDMO Market Size and Growth Rate (M USD)
Figure 48. South America Oligonucleotide CDMO Market Size Market Share by Country in 2024
Figure 49. Brazil Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 50. Argentina Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 51. Columbia Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 52. Middle East and Africa Oligonucleotide CDMO Market Size and Growth Rate (M USD)
Figure 53. Middle East and Africa Oligonucleotide CDMO Market Size Market Share by Region in 2024
Figure 54. Saudi Arabia Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 55. UAE Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 56. Egypt Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. Nigeria Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 58. South Africa Oligonucleotide CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. Global Oligonucleotide CDMO Market Size Forecast by Value (2020-2035) & (M USD)
Figure 60. Global Oligonucleotide CDMO Market Share Forecast by Type (2026-2035)
Figure 61. Global Oligonucleotide CDMO Market Share Forecast by Application (2026-2035)
